Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
PanGIA Biotech
Delray Beach, Florida, USA
- Ownership
- Private
- Development stage
- Other
01
Overview
PanGIA Biotech's AI/ML-powered, urine-based liquid biopsy shows high sensitivity and specificity for early prostate cancer detection, validated in a prospective study presented at ASCO 2025; expansion to other cancers is underway with a multi-cancer clinical study launched in 2024.[8][7][3][2]
- Therapeutic areas
- Oncology
- Modalities
- Diagnostic testArtificial intelligence/ML-integrated platform
- Industry
- Molecular Diagnostics
02
Partnerships
Canary Oncoceutics (commercialization partnership for prostate assay in India)
Beyond the preview
Go deeper on PanGIA Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PanGIA Biotech.